Lynparza 50 Mg

MRP  150,000.0 Inc GST

Lynparza 50 Mg

MRP  150,000.0 Inc GST

ASTRA ZENECA

GENERIC NAME : OLAPARIB

PACKING : 1 BOTTEL – 112 CAPSULE

Description

Lynparza 50 Mg

ASTRA ZENECA

GENERIC NAME : OLAPARIB

PACKING : 1 BOTTEL – 112 CAPSULE

lynparza 50mg

Lynparza Dosage And Uses

Ovarian Cancer

Repetitive ovarian malignancy

Demonstrated as upkeep treatment for repetitive ovarian malignancy (counting epithelial ovarian, fallopian cylinder or essential peritoneal disease) in grown-ups who are in finished or fractional reaction to platinum-based chemotherapy

300 mg PO BID

Proceed until ailment movement, inadmissible harmfulness

Progressed ovarian malignancy (monotherapy)

Shown as first-line upkeep treatment for pernicious or suspected harmful substantial or germline BRCA-changed (gBRCAm) progressed ovarian disease in patients who are in finished or halfway reaction to first-line platinum-based chemotherapy

300 mg PO BID

Proceed until sickness movement, unsuitable harmfulness, or consummation of 2 years of treatment

Consummation of 2 years of treatment

Patients with complete reaction (no radiologic proof): Stop treatment

Patients with proof of illness and may profit by consistent treatment: Treat past 2 years

Progressed ovarian malignant growth (blend treatment)

Shown as a first-line support treatment for cutting edge ovarian disease in mix with bevacizumab for grown-ups who are in finished or halfway reaction to first-line platinum-based chemotherapy and whose malignant growth is related with homologous recombination inadequacy (HRD) positive status characterized by either a pernicious or suspected injurious BRCA change, as well as genomic precariousness

Olaparib 300 mg PO BID, in addition to

Bevacizumab 15 mg/kg IV q3Weeks for a sum of 15 months (counting with chemotherapy and as support)

Proceed until infection movement, unsuitable poisonousness, or fulfillment of 2 years of treatment

Allude to recommending data for bevacizumab when utilized in blend with olaparib for more data

Finishing of 2 years of treatment

Patients with complete reaction (no radiologic proof): Stop treatment

Patients with proof of infection and may profit by ceaseless treatment: Treat past 2 years

Progressed ovarian malignant growth (after ≥3 lines of chemotherapy)

Demonstrated for treatment of grown-ups with harmful or suspected malicious gBRCAm progressed ovarian malignancy who have been treated with ≥3 earlier lines of chemotherapy

300 mg PO BID

Proceed with treatment until ailment movement or unsatisfactory poisonousness

Breast Cancer

Shown for malicious or suspected injurious gBRCAm, human epidermal development factor receptor 2 (HER2)- negative metastatic bosom malignancy

Patients who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting

Patients with hormone receptor (HR)- positive bosom malignancy ought to have been treated with earlier endocrine treatment or be viewed as improper for endocrine treatment

300 mg PO BID

Proceed with treatment until malady movement or unsuitable harmfulness

Pancreatic Cancer

Demonstrated for first-line support treatment of grown-ups with injurious or suspected harmful gBRCAm metastatic pancreatic adenocarcinoma whose sickness has not advanced on in any event four months of a first-line platinum-based chemotherapy routine

300 mg PO BID

Proceed with treatment until sickness movement or inadmissible poisonousness

Metastatic Castration-Resistant Prostate Cancer

Shown for malicious or suspected pernicious germline or substantial homologous recombination fix (HRR) quality changed metastatic emasculation safe prostate malignant growth (mCRPC) in grown-ups who have advanced after earlier treatment with enzalutamide or abiraterone

300 mg PO BID

Proceed until illness movement or inadmissible poisonousness

Ought to likewise get a gonadotropin-discharging hormone (GnRH) simple simultaneously or ought to have had two-sided orchiectomy.

What is Lynparza used for?

LYNPARZA is a doctor prescribed medication used to treat grown-ups who have: progressed ovarian disease, fallopian tube malignant growth, or essential peritoneal malignant growth with a particular kind of acquired (germline) or gained (physical) anomalous BRCA quality.

How long can you take Lynparza?

Half of the individuals taking Lynparza went at any rate 7 months without their malignant growth deteriorating. In examination, half of the individuals taking chemotherapy went in any event 4.2 months without their malignant growth deteriorating.

What are the side effects of Lynparza?

low levels of iron in the blood (anemia), nausea, fatigue, weakness, vomiting, diarrhea, distortion of taste, indigestion,

Can you drink alcohol on Lynparza?

You may take olaparib tablets with food or on a vacant stomach. ... Keep away from grapefruit and grapefruit juice for the length of your treatment, as these may connect with olaparib. • The drinking of liquor (in modest quantities) doesn't seem to influence the security or value of olaparib.

Is Lynparza considered chemotherapy?

Olaparib. Olaparib is the conventional for the exchange chemotherapy sedate Lynparza™. Now and again, human services experts may utilize the exchange name Lynparza™ when alluding to the nonexclusive medication name olaparib. Medication type: Olaparib is a focused on treatment.

Dosage Modifications

The executives of unfriendly responses

Consider portion interference or portion decrease to oversee unfavorable responses

Tablets

Suggested portion decrease: 250 mg (one 150-mg tablet and one 100-mg tablet) PO BID

In the event that a further last portion decrease is required, at that point diminish to 200 mg (two 100-mg tablets) PO BID

Coadministration with CYP3A inhibitors

Solid or moderate CYP3A inhibitors: Avoid use, think about other options

On the off chance that solid CYP3A inhibitors can’t be kept away from Reduce olaparib portion to 100 mg (one 100-mg tablet) PO BID

On the off chance that moderate CYP3A inhibitors can’t be kept away from Reduce olaparib portion to 150 mg (one 150-mg tablet) PO BID

Hepatic impedance

Mellow to direct hepatic disability (Child-Pugh Class An and B): No measurements alteration fundamental

Serious hepatic disability (Child-Pugh Class C): Not examined

Renal impedance

Mellow (CrCl 50-80 mL/min): No measurement alteration important

Moderate (CrCl 31-50 mL/min): Reduce portion to 200 mg (two 100-mg tablets) BID

Serious (CrCl <30 mL/min or dialysis): Not assessed

Dosing Considerations

Withdrawal of capsules

In 2017, FDA announced olaparib containers were being eliminated of the US advertise

Containers were pulled back from the market to keep away from disarray and potential dosing mistakes with the tablets, and to lessen the pill trouble

Patient choice

Select patients for treatment depends on an FDA-affirmed partner indicative for olaparib

Data on FDA-affirmed test for the recognition of BRCA transformations is accessible at http://www.fda.gov/companiondiagnostics

Signs bolstered by indicative tests

gBRCAm HER2-negative metastatic bosom malignant growth

Progressed gBRCAm ovarian malignant growth

First-line support treatment for BRCA-transformed progressed ovarian disease

Metastatic pancreatic adenocarcinoma

Germline or substantial HRR quality transformed mCRPC.

Lynparza Side Effects

Treatment for BRCA-changed Advanced Ovarian

Diminished hemoglobin

Expanded mean corpuscular volume

Sickness

Abatement leukocytes

Exhaustion

Diminished lymphocytes

Diminished ANC

Stomach Pain

Regurgitating

Weakness

Looseness of the bowels

Diminished platelets

Expanded serum creatinine

Clogging

Upper respiratory tract contamination (eg, flu, nasopharyngitis, bronchitis)

Dysgeusia

Weakness, Grade 3 or 4

Wooziness

Diminished hunger

Diminished hemoglobin, Grade 3 or 4

Neutropenia

Dyspepsia

Dyspnea

Diminished lymphocytes, Grade 3 or 4

Urinary tract contamination

Thrombocytopenia

Stomatitis

Maintenance Treatment for Recurrent Advanced Ovarian

Expanded mean corpuscular volume

Diminished hemoglobin

Queasiness

Diminished leukocytes

Diminished lymphocytes

Exhaustion

Diminished ANC

Weakness

Expanded serum creatinine

Diminished platelets

Spewing

Upper respiratory tract disease

Looseness of the bowels

Arthralgia/myalgia

Dysgeusia

Cerebral pain

Diminished craving

Stomatitis

Neutropenia

Leukopenia

Hypomagnesemia

Thrombocytopenia

Wooziness

Dyspepsia

Expanded creatinine

BRCA-transformed Advanced Ovarian

Support treatment

Neutropenia, Grade 3 or 4

Exhaustion, Grade 3 or 4

Leukopenia, Grade 3 or 4

Looseness of the bowels, Grade 3 or 4

Stomach torment, Grade 3 or 4

Thrombocytopenia, Grade 3 or 4

Queasiness, Grade 3 or 4

Maintenance Treatment for Recurrent Advanced Ovarian

Edema

Rash

Exhaustion, Grade 3 or 4

Queasiness, Grade 3 or 4

Spewing, Grade 3 or 4

Looseness of the bowels, Grade 3 or 4

Lymphopenia

Cerebral pain, Grade 3 or 4

Stomatitis, Grade 3 or 4

Postmarketing Reports

Extreme touchiness (rash, dermatitis)

Thrombocytopenia

Dysgeusia

Lymphopenia

Wooziness

Stomatitis

Upper stomach pain.